Clinical Research Directory

Inclusion Criteria: 1. Male and female patients ≥18 years of age. 2. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas, measurable according to the RECIST 1.1. 3. Diagnosed with metastatic disease within 6 weeks before enrollment. 4. Treatment-naïve patients with metastatic pancreatic adenocarcinoma who have received no previous systemic therapy (except adjuvant or neoadjuvant therapy if progression occurred \>6 months from last treatment or surgery, respectively, and no prior nab-paclitaxel). 5. Adequate hematologic, hepatic, and renal function, including: * Hemoglobin ≥9 g/dL * Absolute neutrophil count ≥1500/mm3 * Platelet count ≥100 000/mm3 * Total bilirubin ≤1.25 × upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN * Albumin ≥3 mg/dL * Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥50 mL/min as determined by the Cockcroft-Gault equation. 6. ECOG performance status of 0 or 1. 7. For women of childbearing potential, a negative serum pregnancy test result at Screening. 8. Willing to use 2 medically accepted and effective methods of contraception from the list below during the study (both men and women as appropriate) and for 3 months after the last dose of study drug: 1. Established use of oral, injected, or implanted hormonal methods of contraception 2. Placement of an intrauterine device or intrauterine system 3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository 4. Male sterilization (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate) 5. True abstinence (when this is in line with the preferred and usual lifestyle of the patient). 9. Patient must be able to provide written informed consent for participation in the study. 10. Life expectancy ≥12 weeks as assessed by the Investigator. Exclusion Criteria: 1. Islet-cell neoplasms or locally advanced disease. 2. Chemo-, hormone-, or immunotherapy or investigational drug at Screening or prior to enrollment. 3. Treatment with any drug(s) known to be a strong inhibitor or inducer of CYP2C19,CYP3A4, CYP2C8, and CYP2E1 within 14 days of the date of first administration of study drug and during study treatment. 4. Other malignancies diagnosed within the past 5 years (other than curatively treated cervical cancer in situ, nonmelanoma skin cancer, superficial bladder tumors Ta \[noninvasive tumor\] and TIS \[carcinoma in situ\], or nonmetastatic prostate cancer Stage 1 to 2, which has been previously treated with surgery or radiation therapy, and serum prostate-specific antigen is within normal limits \[test performed within the past 12 months prior to the date of first administration of study drug\]). 5. Patients with any serious active infection (ie, requiring an IV antibiotic, antifungal, or antiviral agent). 6. Patients with known human immunodeficiency virus, active hepatitis B, or active hepatitis C. 7. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug. 8. Known or suspected substance abuse or alcohol abuse. 9. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study treatment, or compromise the ability of the patient to give written informed consent. 10. Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea, (eg, Crohn's disease), malabsorption, or CTCAE Grade \>2 diarrhea of any etiology at baseline. 11. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing an effective method of contraception. 12. Any known hypersensitivity to any component of nab-paclitaxel, gemcitabine, or antroquinonol.